Clinical Trials
Leading Innovation Through Clinical Research
Gregory Rhodes MD Cancer Center, a part of BASS Medical Group, is committed to advancing cancer care through active participation in clinical trials. These research studies explore new treatments, medications, and diagnostic approaches that have the potential to transform how we prevent, detect, and treat cancer.
Our patients gain access to cutting-edge therapies often not yet available outside of the research setting—while helping advance the science that shapes tomorrow’s standards of care.
Open Clinical Trials
The Gregory Rhodes MD Cancer Center, part of BASS Medical Group, provides advanced, compassionate care for a wide range of cancers. Our multidisciplinary team uses leading-edge technology and personalized treatment plans to support every patient through diagnosis, treatment, and recovery.
Breast Cancer Locator Study
The Breast Cancer Locator Study is investigating the effectiveness of the Breast Cancer Locator System in guiding partial mastectomy for breast cancer compared to traditional wire localization.
Eligibility Criteria
Women Aged >18 years Histologic diagnosis of invasive breast cancer or DCIS Non-palpable, unifocal tumor; possible satellite lesions <= 2cm from primary are eligible Tumor >= 1cm in diameter visible on prone breast MRI imaging and mammography
Study Objective
To determine whether the Breast Cancer Locator System can improve a surgeon’s ability to reduce positive margins compared to traditional wire localization.
FRNM-005 Study
The FRNM-005 Study is a prospective blood sample collection study aimed at developing a method for detecting colorectal cancer (CRC) and advanced adenomas.
Cohort B (Focus Cohort)
Participants Aged 45-85 Treatment naive Confirmed CRC or Advanced Adenoma
Cohort A
Participants at average risk Aged 45-85 Blood draw pre-colonoscopy
Study Details
Blood draw volume: 50 mL (5 x 10mL tubes)
PRESERVE-003 Study
The PRESERVE-003 Study is a Phase 3 clinical trial investigating the safety and efficacy of a next-generation anti-CTLA-4 antibody, gotistobart (ONC-392/BNT316), in patients with metastatic non-small cell lung cancer (NSCLC) who have experienced disease progression on anti-PD-1/PD-L1 antibody-based therapy.
Study Objective
To evaluate whether gotistobart can prolong the life of NSCLC patients compared to the chemotherapy agent docetaxel.
Study Details
Patients will be randomized to receive treatment with either gotistobart or docetaxel via intravenous infusion once every 21 days for up to 17 cycles over approximately one year. Open to patients with metastatic NSCLC who have experienced disease progression on anti-PD-1/PD-L1 antibody-based therapy.
BMG Emerging Scholars Program
Gain real-world experience in medicine, research, and innovation through our immersive program for high school students. Join the next generation of healthcare leaders at Gregory Rhodes MD Cancer Center.
Explore the ProgramGet in touch with the Clinical Trials Department
If you are interested in participating in any of these studies or would like more information, please contact Gregory Rhodes MD Cancer Center. Your participation could contribute to advancements in cancer treatment and benefit patients worldwide. Thank you for considering joining us in the fight against cancer.
Contact the Clinical Trials Department for more information:
Brenna Lindsey, MPH
Brenna.lindsey@bassmedicalgroup.com
(925) 433-8786
575 Lennon Lane, Suite 153
Walnut Creek, CA 94598
Disclaimer: Participation in clinical trials is voluntary, and potential risks and benefits will be discussed with qualified medical personnel.